Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Early Inflammatory Signatures of IPMN Progression

Project description

Pancreatic cancer: precision biomarkers for early detection

Pancreatic ductal adenocarcinoma (PDAC) exhibits extremely poor prognosis, largely due to late diagnosis and the absence of early biomarkers. Intraductal papillary mucinous neoplasms (IPMNs) are precancerous pancreatic cysts that may progress into PDAC. These common PDAC precursors are thought to be responsible for 20 % to 30 % of all PDAC cases. However, current diagnostic criteria often misdiagnose or miss IPMNs, leading to erroneous classification and decision-making. The ERC-funded easi-IPMN project builds on a previously discovered gene signature that identifies pre-neoplastic cells. The goal is to validate the signature as a biomarker to accurately classify IPMN patients and determine PDAC risk, facilitating early detection and personalised management.

Objective

Pancreatic Ductal Adenocarcinoma (PDAC) is a lethal cancer with rising global incidence and poor survival rates. Early PDAC diagnosis is hampered by non-specific symptoms and by the absence of reliable early biomarkers. On the other hand, intraductal papillary mucinous neoplasms (IPMNs), precursor lesions of PDAC, are commonly found during abdominal imaging. IPMN management lacks consensus, leading to inefficient decisions decisions on empirical assessments of high-risk stigmata (HRS) and worrisome features (WF). There is an urgent need for precise IPMN patient classification to guide personalized treatment decisions, reducing unnecessary surgeries and late interventions.

Our ERC-StG project identified a gene signature marking pre-neoplastic cells in PDAC precursor lesions. We propose testing this signature as a biomarker for PDAC in IPMN patients, to distinguish those at high-risk or low-risk of progressing to invasive carcinoma. Successful validation of the signature as a biomarker holds benefit clinical management of IPMN patients, mitigating the economic and societal consequences of over-treatment and under-treatment. At the same time, these activities should advance early detection in pancreatic cancer. Our multidisciplinary approach and groundbreaking discoveries put us in the best position to tackle this key challenge in immuno-oncology.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

UNIVERSITA VITA-SALUTE SAN RAFFAELE
Net EU contribution
€ 115 000,00
Address
VIA OLGETTINA 58
20132 Milano
Italy
Region
Nord-Ovest Lombardia Milano
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (2)